ADIAL PHARMACEUTICALS, INC. financial data

Symbol
ADIL on Nasdaq
Location
Charlottesville, VA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 381% %
Debt-to-equity 29% %
Return On Equity -198% % 23%
Return On Assets -154% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 23,987,587 shares 274%
Common Stock, Shares, Outstanding 23,836,383 shares 272%
Entity Public Float $4,832,073 USD -10%
Common Stock, Value, Issued $23,836 USD 272%
Weighted Average Number of Shares Outstanding, Basic 22,171,309 shares 280%
Weighted Average Number of Shares Outstanding, Diluted 22,171,309 shares 280%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $2,731,068 USD 11%
General and Administrative Expense $5,123,746 USD 2%
Operating Income (Loss) $7,854,814 USD -5.1%
Nonoperating Income (Expense) $196,984 USD 96%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $2,191,803 USD -63%
Net Income (Loss) Attributable to Parent $8,051,798 USD 38%
Earnings Per Share, Basic 0 USD/shares 98%
Earnings Per Share, Diluted 0 USD/shares 98%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $4,606,289 USD -11%
Assets, Current $5,013,832 USD -11%
Intangible Assets, Net (Excluding Goodwill) $2,925 USD -16%
Assets $5,659,847 USD -16%
Accounts Payable, Current $556,284 USD 75%
Accrued Liabilities, Current $598,472 USD 19%
Liabilities, Current $1,154,756 USD 39%
Liabilities $1,154,756 USD 39%
Retained Earnings (Accumulated Deficit) $87,976,331 USD -10%
Stockholders' Equity Attributable to Parent $4,505,091 USD -23%
Liabilities and Equity $5,659,847 USD -16%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,585,393 USD 2.5%
Net Cash Provided by (Used in) Financing Activities $50,648 USD -99%
Net Cash Provided by (Used in) Investing Activities $150,000 USD
Common Stock, Shares Authorized 100,000,000 shares 100%
Common Stock, Shares, Issued 23,836,383 shares 272%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4,606,289 USD -11%
Deferred Tax Assets, Valuation Allowance $15,559,357 USD 15%
Deferred Tax Assets, Gross $38,321 USD 8669%
Deferred Tax Assets, Operating Loss Carryforwards $13,963,767 USD 14%
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Additional Paid in Capital $92,457,586 USD 7.8%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets $141 USD 0%
Share-based Payment Arrangement, Expense $688,366 USD -23%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%